AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 40.17 |
Market Cap | 2.50B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.21 |
PE Ratio (ttm) | -20.27 |
Forward PE | n/a |
Analyst | Buy |
Ask | 71.6 |
Volume | 961,231 |
Avg. Volume (20D) | 834,472 |
Open | 45.37 |
Previous Close | 45.35 |
Day's Range | 44.16 - 45.79 |
52-Week Range | 38.27 - 65.03 |
Beta | undefined |
About ENOV
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic ev...
Analyst Forecast
According to 8 analyst ratings, the average rating for ENOV stock is "Buy." The 12-month stock price forecast is $68.5, which is an increase of 52.88% from the latest price.
Next Earnings Release
Analysts project revenue of $554.57M, reflecting a 21.88% YoY growth and earnings per share of 0.91, making a 15.19% increase YoY.